Results 51 to 60 of about 12,135 (165)
ABSTRACT Plasmodium vivax (P. vivax) malaria, once regarded as a comparatively benign infection, is increasingly recognized as a cause of severe, potentially life‐threatening multisystem disease. Concurrent secondary hemophagocytic lymphohistiocytosis (HLH), disseminated intravascular coagulation (DIC), and acute pancreatitis complicating P.
Tasnim Nafian +5 more
wiley +1 more source
Use of artemether-lumefantrine in the treatment of asymptomatic-malaria infection in HIV-positive and HIVnegative Nigerian adults. [PDF]
Malaria /HIV co-infection is a major challenge to public health in developing countries and yet potential drug-drug interactions between antimalarial and antiviral regimens have not been adequately investigated in people with both HIV and Plasmodium ...
Chijioke-Nwauche, IN
core +1 more source
CYP2B6*6 Genotype Specific Differences in Artemether-Lumefantrine Disposition in Healthy Volunteers [PDF]
Cytochrome P450 2B6 (CYP2B6) is involved in the metabolism of the antimalarial drugs artemether and lumefantrine. Here we investigated the effect of CYP2B6*6 on the plasma pharmacokinetics of artemether, lumefantrine, and their metabolites in healthy ...
Winterberg, Markus +19 more
core +1 more source
Background The influx of substandard and falsified medicines is a global public health challenge and its rapid detection is a key solution to the menace. This study used three screening methods and one confirmatory method for the quality assessment of 25
Kwabena Frimpong-Manso Opuni +8 more
doaj +1 more source
ABSTRACT Malaria‐associated secondary HLH, though rare, is often overlooked. Clinicians should maintain a high‐index of suspicion in travelers returning from malaria‐endemic regions who develop severe to rapidly worsening inflammatory illness, as early recognition is critical for survival.
Indresh Yadav +4 more
wiley +1 more source
Safety of artemether-lumefantrine exposure in first trimester of pregnancy : an observational cohort [PDF]
There is limited data available regarding safety profile of artemisinins in early pregnancy. They are, therefore, not recommended by WHO as a first-line treatment for malaria in first trimester due to associated embryo-foetal toxicity in animal studies ...
Abdulla, Salim +17 more
core +1 more source
Background The lipid self-emulsifying system has been advanced as a promising delivery vehicle for improving the solubility and bioavailability of artemether and lumefantrine. However, the observed kinetic instability (propensity of lumefantrine to rapid
Onyinyechi Lydia Ugorji +5 more
doaj +1 more source
Background Artemether and Lumefantrine are widely used antimalarial agents whose simultaneous quantification in tablet formulations is essential for quality control.Objectives To develop and validate a simple accurate and robust ...
Lekhana A M +2 more
doaj +1 more source
Background The recommendation of artemisinin combination therapy (ACT) as first-line treatment for uncomplicated falciparum malaria is supported by a plethora of high quality clinical trials.
Mombo-Ngoma Ghyslain +12 more
doaj +1 more source
Monitoring of the Sensitivity In Vivo of Plasmodium falciparum to Artemether-Lumefantrine in Mali
In Mali, since 2007, artemether-lumefantrine has been the first choice against uncomplicated malaria. Despite its effectiveness, a rapid selection of markers of resistance to partner drugs has been documented.
Modibo Diarra +13 more
doaj +1 more source

